Therapy Areas: Infectious Diseases
AmpliPhi Biosciences Claims Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01
18 September 2018 - - US-based clinical-stage biotechnology company AmpliPhi Biosciences Corp. (NYSE American: APHB) had a Type B Pre-IND meeting with the US Food and Drug Administration and has now r...
Virion Names King as President and CEO and Isabel Najera as CSO
17 September 2018 - - UK-based biologicals developer Virion Biotherapeutics has appointed Vanessa King, PhD, as president and chief executive officer and Isabel Najera, PhD, as chief scientific office...
TechnoVax Awarded USD 1.5m NIH Grant to Further Develop a Universal VLP-Based Influenza Vaccine
13 September 2018 - - US-based biotechnology vaccines developer TechnoVax, Inc has received a two-year USD 1.481m SBIR-II grant from the National Institute of Allergy and Infectious Diseases (NIAID) o...
Novocure and Zai Lab Ink License Agreement for Tumor Treating Fields in Greater China
12 September 2018 - - Jersey-based oncology company Novocure (NASDAQ: NVCR) and China-based biopharmaceutical company Zai Lab (NASDAQ: ZLAB) have inked an exclusive license agreement for Tumor Treatin...
Human Trials Begin for DesignMedix Anti-Malarial Drug Developed to Overcome Growing Drug Resistance
12 September 2018 - - US-based small molecule drug developer DesignMedix's lead product, experimental anti-malaria medicine DM1157, has begun human clinical trials, the company said.

...
US Merck Says Zerbaxa Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
11 September 2018 - - Apivotal Phase 3 clinical study evaluating US-based pharmaceutical company Merck and Co., Inc.'s (NYSE: MRK) antibiotic Zerbaxa (ceftolozane and tazobactam) at an investigat...